User login
Key clinical point: Cemiplimab appears to have the most favorable benefit-risk ratio among the analyzed immune checkpoint inhibitors (ICI) for the treatment of patients with nonsmall cell lung cancer (NSCLC).
Major finding: Cemiplimab was associated with the lowest hazard ratio (HR) for overall survival (OS) relative to chemotherapy (HR 0.68; 95% CI 0. 57-0.81), translating to the highest surface under the cumulative ranking curve (SUCRA) value of 49.5%. Additionally, cemiplimab was associated with the lowest incidence of treatment-related adverse events (TRAE) relative to chemotherapy (odds ratio 0.17; 95% credible interval 0.06-0.45).
Study details: The data come from a network meta-analysis of 13 randomized controlled trials (n = 7795). The SUCRA values of all ICI (cemiplimab, avelumab, atezolizumab, nivolumab, and pembrolizumab) were determined for OS and TRAE.
Disclosures: No funding source was identified. The authors declared no conflicts of interest.
Source: Jiang M et al. Comparative efficacy and safety of anti-PD-1/PD-L1 for the treatment of non-small cell lung cancer: A network meta-analysis of 13 randomized controlled studies. Front Oncol. 2022;12:827050 (May 10). Doi: 10.3389/fonc.2022.827050
Key clinical point: Cemiplimab appears to have the most favorable benefit-risk ratio among the analyzed immune checkpoint inhibitors (ICI) for the treatment of patients with nonsmall cell lung cancer (NSCLC).
Major finding: Cemiplimab was associated with the lowest hazard ratio (HR) for overall survival (OS) relative to chemotherapy (HR 0.68; 95% CI 0. 57-0.81), translating to the highest surface under the cumulative ranking curve (SUCRA) value of 49.5%. Additionally, cemiplimab was associated with the lowest incidence of treatment-related adverse events (TRAE) relative to chemotherapy (odds ratio 0.17; 95% credible interval 0.06-0.45).
Study details: The data come from a network meta-analysis of 13 randomized controlled trials (n = 7795). The SUCRA values of all ICI (cemiplimab, avelumab, atezolizumab, nivolumab, and pembrolizumab) were determined for OS and TRAE.
Disclosures: No funding source was identified. The authors declared no conflicts of interest.
Source: Jiang M et al. Comparative efficacy and safety of anti-PD-1/PD-L1 for the treatment of non-small cell lung cancer: A network meta-analysis of 13 randomized controlled studies. Front Oncol. 2022;12:827050 (May 10). Doi: 10.3389/fonc.2022.827050
Key clinical point: Cemiplimab appears to have the most favorable benefit-risk ratio among the analyzed immune checkpoint inhibitors (ICI) for the treatment of patients with nonsmall cell lung cancer (NSCLC).
Major finding: Cemiplimab was associated with the lowest hazard ratio (HR) for overall survival (OS) relative to chemotherapy (HR 0.68; 95% CI 0. 57-0.81), translating to the highest surface under the cumulative ranking curve (SUCRA) value of 49.5%. Additionally, cemiplimab was associated with the lowest incidence of treatment-related adverse events (TRAE) relative to chemotherapy (odds ratio 0.17; 95% credible interval 0.06-0.45).
Study details: The data come from a network meta-analysis of 13 randomized controlled trials (n = 7795). The SUCRA values of all ICI (cemiplimab, avelumab, atezolizumab, nivolumab, and pembrolizumab) were determined for OS and TRAE.
Disclosures: No funding source was identified. The authors declared no conflicts of interest.
Source: Jiang M et al. Comparative efficacy and safety of anti-PD-1/PD-L1 for the treatment of non-small cell lung cancer: A network meta-analysis of 13 randomized controlled studies. Front Oncol. 2022;12:827050 (May 10). Doi: 10.3389/fonc.2022.827050